Selecta Biosciences Inc. is a clinical-stage biotechnology company with an unrelenting commitment to overcoming immunogenicity with our pioneering ImmTOR™ immune tolerance platform.
Founded in 2008, Selecta is leveraging its clinically-validated ImmTOR platform to develop antigen-specific tolerogenic therapies. With a proven ability to induce tolerance to highly immunogenic molecules, ImmTOR can be leveraged to both amplify the efficacy of biologics, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases.